RxDoctor Payments Data

Aakash Garg, MD

Cardiovascular Disease · Schenectady, NYNPI 1669872495

Payments from drug & device makers

$164,179in general payments, 2019–2025

Across 977 payments — averaging $168.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cathworks, Inc.$69K
  • Edwards Lifesciences$29K
  • Medtronic$28K
  • Chiesi USA, Inc.$14K
  • Abbott$10K
  • Boston Scientific$4K
  • plus $10K from 31 others

What the payments were for

  • Consulting fees$26,67827%
  • Speaking & faculty fees$3,4003%
  • Grants$6,1056%
  • Travel & lodging$31,34132%
  • Food & beverage$30,65331%
  • Education$3900%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$164,179 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$226,568
Medicare patients
339
Services billed
967

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban69$86,886
JardianceEmpagliflozin31$39,380
BrilintaTicagrelor24$28,255
FarxigaDapagliflozin Propanediol12$11,098
Metoprolol Succinate96$1,255
ClopidogrelClopidogrel Bisulfate74$1,022
Irbesartan23$748
Atorvastatin Calcium61$708
Valsartan22$671
Torsemide37$667
Rosuvastatin Calcium24$488
Potassium Chloride19$464
Losartan Potassium33$463
Amlodipine Besylate65$340
Nitroglycerin14$302

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$334$86,88669 claims
Boehringer IngelheimJardiance$373$39,38031 claims
AstraZenecaBrilinta, Farxiga$302$39,35336 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Schenectady

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →